G-NK cells + mAb

About Indapta Therapeutics

Indapta Therapeutics is a private, clinical-stage biotech harnessing a unique subset of natural killer cells, known as G-NK cells, for off-the-shelf cellular immunotherapy. Founded in 2018, the company is advancing its platform into Phase 1 trials for hematologic cancers (in combination with monoclonal antibodies) and multiple sclerosis. With backing from prominent venture capital firms and a seasoned leadership team, Indapta aims to address significant limitations in current autologous cell therapies and autoimmune disease treatments.

Therapeutic Areas